Biotron Ltd
ASX:BIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biotron Ltd
Total Current Liabilities
Biotron Ltd
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biotron Ltd
ASX:BIT
|
Total Current Liabilities
AU$1.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
15%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Current Liabilities
$128.1m
|
CAGR 3-Years
33%
|
CAGR 5-Years
7%
|
CAGR 10-Years
12%
|
|
|
CSL Ltd
ASX:CSL
|
Total Current Liabilities
$4.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Total Current Liabilities
AU$17.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
16%
|
CAGR 10-Years
22%
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Current Liabilities
AU$231.6m
|
CAGR 3-Years
39%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Current Liabilities
AU$11m
|
CAGR 3-Years
11%
|
CAGR 5-Years
57%
|
CAGR 10-Years
29%
|
|
Biotron Ltd
Glance View
Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The company is engaged in developing small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1). The firm's lead drug, BIT225 is in Phase II clinical development for the treatment of HIV-1 and HCV infections. BIT225 is a small-molecule anti-viral compound that works to inhibit the viroporin mechanism of Viral Protein U (Vpu). BIT225, in HIV-1, offers eradicate reservoirs of virus found in long-lived macrophage cells, which contribute to the need for life-long treatment with antiretroviral drugs. For HCV, BIT225 offers as a class of oral direct-acting antiviral (DAA) drug. The firm progresses its Hepatitis B virus (HBV) program. The company also designs and develops drugs drugs that target a class of viral proteins known as viroporins.
See Also
What is Biotron Ltd's Total Current Liabilities?
Total Current Liabilities
1.2m
AUD
Based on the financial report for Dec 31, 2025, Biotron Ltd's Total Current Liabilities amounts to 1.2m AUD.
What is Biotron Ltd's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
15%
Over the last year, the Total Current Liabilities growth was 131%. The average annual Total Current Liabilities growth rates for Biotron Ltd have been 15% over the past three years , 12% over the past five years , and 15% over the past ten years .
